



REVIEWING DIFFERENT ANTI-BIOLOGICAL PROPERTIES OF HETEROCYCLIC COMPOUNDS

RASHI JAISWAL

RESEARCH SCHOLAR SUNRISE UNIVERSITY ALWAR

DR. JAGADISH CHANDRA PATI

ASSOCIATE PROFESSOR SUNRISE UNIVERSITY ALWAR

ABSTRACT

One of the most important and constantly evolving fields for medicinal chemists is the discovery and development of anticancer drugs. Due to their diverse chemotherapeutic relevance, pyrimidine derivatives have been employed widely as significant pharmacophores and synthons in the field of organic chemistry and drug development. They have also played a significant part in the history of heterocyclic chemistry. This nucleus has received a lot of attention from researchers. Due to their numerous medical benefits, including their antiviral, anticancer, antibacterial, antihypertensive, tyrosine kinase inhibitory, COX-2 inhibitory, and calcium channel blocking capabilities, pyrimidines have been revealed to exhibit biomimetic and reactive pharmacophores. One of the potential causes of their activity might be the presence of pyrimidine bases, such as thymine, cytosine, and uracil, which are crucial components of nucleic acids. Vitamins including riboflavin, thiamine, and folic acid include the pyrimidine ring. Barbituric acid and its many derivatives, which are employed as hypnotics, also contain the pyrimidine nucleus. We were interested in creating some novel dihydropyrimidine derivatives and testing them for in vitro anticancer, antibacterial, and antifungal activity in light of these fascinating biological activities. This study was conducted to provide new developments in the evaluation of pyrimidine in general and its numerous applications in both chemistry and pharmacy.

Keywords: -Agents, Drugs, Chemical, Activity, Properties.

I. INTRODUCTION

Heterocyclic compounds, often known as heterocycles, are organic chemical compounds having a ring-like structure that includes one or more heteroatoms. Heterocycles can be both cyclic and acyclic. The general structure of heterocycles is similar to that of cyclic organic compounds, which have only carbon atom in their structure, but the substitute of one or more carbon atoms by heteroatoms gives heterocycles physico-chemical properties that are distinct from those of all carbon ring analogs. Heterocycles involve a wide range of uses, including agrochemical, medicinal, and veterinary. Such compounds are also used in sanitizers, antioxidants, copolymers,



corrosion inhibitors, dyestuff, *etc.* Heterocycles are currently employed in the production of a wide range of organic chemical substances. Several compounds, mostly of natural origin, such as alkaloids, morphine, vinblastine, and reserpine, and a variety of antibiotics, such as cephalosporin, penicillin, and others, include heterocyclic components.

II. ANTIMICROBIAL AGENTS

The term "antimicrobial" refers to a material with the ability to destroy or slow the growth of microorganisms such as bacteria, fungus, viruses, and parasites (anti-parasitic activity). There has been a dramatic rise in the prevalence of infectious diseases caused by microorganisms over the past few decades. Humans and animals alike have been afflicted by infections caused by bacteria, fungi, viruses, and so on. Therefore, this group of medicines represents the 20th century's single most significant contribution to medicinal chemistry. The research and development of a more powerful and efficient antimicrobial agent has received considerable attention. Antibacterial and antifungal agents, which have medical applications, have been the primary focus of research during the development of antimicrobial agents. The large numbers of bacteria during an infection or on the skin's surface are the result of the bacteria's ability to grow and divide.

III. ANTIBACTERIAL AGENTS

Antibacterial are antibiotics that don't work on viruses. In 1877, **Louis Pasteur** demonstrated that soil microorganisms might be used to protect animals from the potentially fatal bacterial illness anthrax.

In 1887, **Rudolf Emmerich** demonstrated that animals infected with streptococcus bacteria and later injected with cholera bacillus were protected from contracting the intestinal infection.

In 1888, the German scientist E. de Freudenreich has successfully identified a bacterial product with antimicrobial activity. Scientists from Freudenreich University of Hildesheim discovered that the *B. procyaneus*, has the potential to eliminate several pathogenic microorganisms. Despite its promise as the first naturally occurring antibiotic, pyocyanase failed to show promise in clinical trials, proving to be toxic and unstable.

British scientist Alexander Fleming discovered in the early 1920s that a component of human tears may lyse bacterial cells. Lysozyme, which Fleming discovered, was the first antibacterial agent discovered in humans.

Fleming made a fortuitous discovery of a second antibacterial agent, penicillin, in 1928, but he was unable to test it in people or animals and stopped publishing about penicillin in 1931.



Ten years after penicillin's finding, in 1939, Howard Florey, Ernst Chain, and Norman Heatly got the penicillium fungus from Fleming and was able to solve the technical hurdles that had troubled him, thereby spectacularly demonstrating penicillin's potency in the clinical context. Even little doses of the medicine in its unrefined form were able to magically cure animals and humans who were close to death from bacterial diseases.

IV. ANTIFUNGAL AGENTS:

Mycoses, or fungal infections, are common and often affect the skin (as in "athlete's foot") or the mucous membranes (as in "thrush"). Most people in temperate regions, such as the United Kingdom, and in good health may safely ignore these pests. When the immune system is suppressed or when they enter the systemic circulation, however, they pose a far greater threat to the host. Fungal infections may be extremely dangerous, and even deadly, when this happens. Here we shall recap quickly. Diseases caused by fungi, and go through the medications that can cure them.

Drugs used to treat fungal infections:

Both naturally occurring antifungal antibiotics like polyenes and echinocandins and synthetic drugs like azoles and fluorinated pyrimidines make up the bulk of the current therapeutic agents. There are several topical treatments available since many illnesses only affect the skin's surface. Systemic antifungal therapy is often only used when absolutely necessary because of the toxicity of several antifungal medications.

Antifungal Antibiotics

Amphotericin

Amphotericin, also known as amphotericin B, is an antifungal compound isolated from *Streptomyces* cultures. According to their molecular structure, these antifungals are members of the polyene family.

Nystatin

Similar in structure and mode of action to the antifungal drug amphotericin, the polyene macrolide antibiotic nystatin goes by the name fungicidin. Although it is effective against *Candida* infections of the skin, mucous membranes, and gastrointestinal tract, it is almost impossible for the drug to be absorbed through the mucous membranes or the skin. Nausea, vomiting, and diarrhoea are some of the possible negative side effects.

Griseofulvin



Cultures of *Penicillium griseofulvum* yielded griseofulvin, a potent but narrow-spectrum antifungal agent. Because of its effect on fungal microtubules, it can be used to halt the growth of fungus by preventing them from dividing. In cases when local therapy has failed due to an infection with the fungus dermatophytes, this medication might be used to treat the affected skin or nails. Other medications have essentially replaced it.

V. ANTITUBERCULAR AGENTS:

Mycobacteria, especially *Mycobacterium tuberculosis*, are responsible for the widespread and sometimes fatal infectious illness known as tuberculosis (or TB, for "Tubercle Bacillus"). Despite its name, tuberculosis may affect any part of the body, including the lungs (as pulmonary TB) and the brain, spinal cord, lymph nodes, blood vessels, kidneys, ureters, bones, joints, and skin. *Mycobacterium bovis*, *Mycobacterium africanum*, *Mycobacterium canetti*, and *Mycobacterium microti* can also cause TB, but they seldom infect healthy individuals.

Tuberculosis (TB) is still the leading infectious cause of mortality and disability worldwide. The causative organism for tuberculosis, *Mycobacterium tuberculosis* (MTB), is present in the bodies of one-third of the world's population. Each year, there are between eight and ten million new TB cases globally, according to the World Health Organization (WHO), and the number is rising. About two million fatalities a year are attributed to tuberculosis, placing it in the top three major causes of mortality from a single infectious agent with malaria and HIV. The most prevalent kind of tuberculosis, which affects the lungs, is very dangerous because it spreads rapidly and can be fatal. Another global health issue is the increased vulnerability to tuberculosis among those living with HIV. Furthermore, the prevalence of multidrug-resistant tuberculosis (MDR-TB) has been rising in several regions, both in the developing world and the developed world. The global resurgence of tuberculosis (TB) and the rapid emergence of multidrug-resistant tuberculosis (MDR-TB) during the past decade (1-17) highlight the importance of developing new antituberculous drugs and new protocols for effective clinical control of TB patients using ordinary antimycobacterial drugs.

VI. CONCLUSION

Heterocyclic compounds are one of the most significant types of organic molecules in medicinal chemistry and they are used as medications for various diseases. Numerous impressive accomplishments have shown that heterocyclic compounds have a wide range of therapeutic drug applications.

Heterocyclic compounds are versatile synthetic targets and key structural units in organic synthesis and medicinal chemistry because of their exciting biological activities. The potential applications of heterocycles as anticancer, anti-inflammatory, antifungal, antibacterial, anti-



Alzheimer's, antiviral, antidiabetic agents, *etc.*, have attracted substantial interest within the pharmaceutical community. Interestingly, an increasing number of heterocycles have been identified as potential drug candidates in ongoing drug development.

REFERENCES:-

1. Yao L, Yin L, Yang H, Zhu DD, Shuai Z, Zhi-Jun L, Hai-Bin G, Zhu HL. Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors. *Bioorg. Med. Chem.* 2012; 20: 4316–4322.
2. Mohamed JA, Jeyabalan GS, Habibullah K, Pankaj S, Ramakant G and Abhimanyu S. Molecular properties prediction and synthesis of novel 1,3,4- oxadiazole analogues as potent antimicrobial and antitubercular agents. *Bioorg. Med. Chem. Lett.* 2011; 21(24):7246-50.
3. Mohammed AfrozBakht, M. Shahar Y, Sami Gaber AH, Saleh I. Al Qasoumi, Abdul S. Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives. *Eur. J. Med. Chem.* 2010; 45: 5862-69.
4. Amit RT, Arif BS, Viresh HS. Synthesis and biological evaluation of some new pyrimidines via a novel chalcone series. *ARKIVOC.* 2008; 2: 210-217.
5. Purohit MN, Chokshi K, Pujar GV, Mayur VC, Shantakumar SM. Synthesis and antibacterial activity of 5-(5'-substituted 1,3,4-oxadiazol-2'-yl) Dihydropyrimidinone derivatives. *Indian J. Hetero. Chem* 2007;16:349-52.
6. Nagalakshmi G. Synthesis, Characterization and antimicrobial activity of some 2,5-disubstituted-1,3,4-oxadiazoles. *Dhaka Univ J Pharm Sci.*2007; 6: 69-75.
7. Maria CSL, Marcus VND, Alessandra CP, Marcelle LF, Rasnisb BG, Thais CM, et. al. Evaluation of anti-tubercular activity of nicotinic and isoniazid analogues. *ARKIVOC.* 2007; 15: 181-91.
8. Vosooghi M, Akbarzadeh T, Fallah A, Fazeli MR, Jamalifar H, Shafiee A. Synthesis and evaluation of 2-(4-nitro-1-imidazolylmethyl)-1,3,4-oxadiazoles for antitubercular activity. *J. Sci. Islamic Republic of Iran.* 2005; 16(2): 145-151.
9. Mogilaiah K, Chowdary DS. Synthesis and antibacterial activity of pyrazole and 1,3,4-oxadiazole derivatives of 2-phenyl-1,8-naphthyridine. *Indian J. Chem.* 2001;40B:43-48.
10. Afaf HE, Fahmy HH and Abdelwahed SH. Synthesis and Antimicrobial Activity of Some New Benzimidazole Derivatives. *Molecules.* 2000; 5(12): 1429-38.